U.S. Markets close in 3 hrs 22 mins

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.84-0.19 (-1.19%)
As of 12:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.03
Bid15.93 x 800
Ask15.97 x 1100
Day's Range15.63 - 16.06
52 Week Range3.04 - 30.38
Avg. Volume416,955
Market Cap936.93M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. – ACRS

    NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION AND FINAL APPROVAL HEARING To: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED ACLARIS THERAPEUTICS, INC. SECURITIES BET

  • GlobeNewswire

    Aclaris Therapeutics to Participate in Upcoming Investor Conferences

    WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference. On Monday, September 13, 2021 at 7:00 a.m. ET, Dr. Neal Walker, the President and CEO of Aclaris, will virtually present a company over

  • GlobeNewswire

    Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

    Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in Moderate to Severe Atopic Dermatitis Announced in JuneAdvancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe Rheumatoid Arthritis in Fourth Quarter of 2021 WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharm